Exacerbation of psoriasis induced by Nivolumab in a patient with stage IIIc gastric adenocarcinoma: A case report and literature review

IF 4.7 Q2 IMMUNOLOGY

Journal of Translational Autoimmunity Pub Date : 2023-01-01 DOI:10.1016/j.jtauto.2023.100193

Xiaojie Sun , Xiaole Mei , Yi Liu

{"title":"Exacerbation of psoriasis induced by Nivolumab in a patient with stage IIIc gastric adenocarcinoma: A case report and literature review","authors":"Xiaojie Sun , Xiaole Mei , Yi Liu","doi":"10.1016/j.jtauto.2023.100193","DOIUrl":null,"url":null,"abstract":"<div><p>Nivolumab, the programmed cell death 1 inhibitor, is a kind of immune checkpoint inhibitor commonly used to treat advanced cancers. Unfortunately, such drugs often induce various immune-related adverse events involving different body systems, with psoriasis being one of the skin toxicities. We report the clinical features of an exacerbated psoriasis induced by using nivolumab after three days in a patient with stage IIIc gastric adenocarcinoma. At the same time, we searched 27 case reports published from 2015 to 2021 over the world and systematically summarized the clinical manifestation of a total of 44 cases with psoriasis caused or exacerbated by Nivolumab. Commonly traditional treatment could be useful, and small molecule drugs such as apremilast are effective among some patients. However, more studies are needed to evaluate the efficacy and safety of biologics or small molecule drugs in treating psoriasis induced by nivolumab.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"6 ","pages":"Article 100193"},"PeriodicalIF":4.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/31/main.PMC9958049.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Autoimmunity","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589909023000060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Nivolumab, the programmed cell death 1 inhibitor, is a kind of immune checkpoint inhibitor commonly used to treat advanced cancers. Unfortunately, such drugs often induce various immune-related adverse events involving different body systems, with psoriasis being one of the skin toxicities. We report the clinical features of an exacerbated psoriasis induced by using nivolumab after three days in a patient with stage IIIc gastric adenocarcinoma. At the same time, we searched 27 case reports published from 2015 to 2021 over the world and systematically summarized the clinical manifestation of a total of 44 cases with psoriasis caused or exacerbated by Nivolumab. Commonly traditional treatment could be useful, and small molecule drugs such as apremilast are effective among some patients. However, more studies are needed to evaluate the efficacy and safety of biologics or small molecule drugs in treating psoriasis induced by nivolumab.

Abstract Image

查看原文本刊更多论文

Nivolumab在IIIc期胃腺癌患者中引起银屑病加重:1例报告和文献复习

Nivolumab是程序性细胞死亡1抑制剂，是一种常用于治疗晚期癌症的免疫检查点抑制剂。不幸的是，这类药物通常会引发涉及不同身体系统的各种免疫相关不良事件，银屑病是皮肤毒性之一。我们报告了一名IIIc期胃腺癌患者在三天后使用尼沃单抗诱发的加重型银屑病的临床特征。同时，我们检索了2015年至2021年全球发表的27例病例报告，系统总结了尼沃单抗引起或加重的44例银屑病患者的临床表现。通常的传统治疗可能是有用的，小分子药物如阿普司特对一些患者有效。然而，还需要更多的研究来评估生物制剂或小分子药物治疗nivolumab诱导的银屑病的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Translational Autoimmunity Medicine-Immunology and Allergy

CiteScore

7.80

自引率

2.60%

发文量

审稿时长

55 days